NVCTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Nuvectis Pharma, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$18.94+0.34 (+1.83%)

Close on Oct 19, 2026

Market cap: $444.64M
P/E (TTM): –
Dividend yield: 0.00%

Nuvectis Pharma, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-Based Compensation	6.03	4.86	4.71	1.71	1.89
Change in Accounts Payable	3.78	-0.27	-0.14	1.85	1.59
Operating Cash Flow	-16	-12	-16	-14	-9.50
Investing Cash Flow	–	0	0	0	–
Stock Issued	–	12	5.29	–	–
Financing Cash Flow	29	12	15	28	15

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -188.0%

Financial strength

Current ratio: 1.68
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 166.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 48.96
Dividend yield: 0.00%